These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 33595792)

  • 1. Population Pharmacokinetic Evaluation of Amikacin Liposome Inhalation Suspension in Patients with Treatment-Refractory Nontuberculous Mycobacterial Lung Disease.
    Rubino CM; Onufrak NJ; van Ingen J; Griffith DE; Bhavnani SM; Yuen DW; Mange KC; Winthrop KL
    Eur J Drug Metab Pharmacokinet; 2021 Mar; 46(2):277-287. PubMed ID: 33595792
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Amikacin Liposome Inhalation Suspension for Treatment-Refractory Lung Disease Caused by
    Griffith DE; Eagle G; Thomson R; Aksamit TR; Hasegawa N; Morimoto K; Addrizzo-Harris DJ; O'Donnell AE; Marras TK; Flume PA; Loebinger MR; Morgan L; Codecasa LR; Hill AT; Ruoss SJ; Yim JJ; Ringshausen FC; Field SK; Philley JV; Wallace RJ; van Ingen J; Coulter C; Nezamis J; Winthrop KL;
    Am J Respir Crit Care Med; 2018 Dec; 198(12):1559-1569. PubMed ID: 30216086
    [No Abstract]   [Full Text] [Related]  

  • 3. Amikacin Liposome Inhalation Suspension: A Review in Mycobacterium avium Complex Lung Disease.
    Shirley M
    Drugs; 2019 Apr; 79(5):555-562. PubMed ID: 30877642
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Amikacin Liposome Inhalation Suspension for Refractory Mycobacterium avium Complex Lung Disease: Sustainability and Durability of Culture Conversion and Safety of Long-term Exposure.
    Griffith DE; Thomson R; Flume PA; Aksamit TR; Field SK; Addrizzo-Harris DJ; Morimoto K; Hoefsloot W; Mange KC; Yuen DW; Ciesielska M; Wallace RJ; van Ingen J; Brown-Elliott BA; Coulter C; Winthrop KL;
    Chest; 2021 Sep; 160(3):831-842. PubMed ID: 33887244
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of Amikacin liposome inhalation suspension for refractory Mycobacterium avium complex pulmonary disease at 6 months post initiation.
    Urabe N; Sakamoto S; Tokita N; Yoshida H; Usui Y; Shimizu H; Sekiya M; Miyoshi S; Nakamura Y; Isobe K; Kishi K
    BMC Pulm Med; 2024 Sep; 24(1):442. PubMed ID: 39256717
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Use of Amikacin Liposome Inhalation Suspension (Arikayce) in the Treatment of Refractory Nontuberculous Mycobacterial Lung Disease in Adults.
    Khan O; Chaudary N
    Drug Des Devel Ther; 2020; 14():2287-2294. PubMed ID: 32606598
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amikacin Liposome Inhalation Suspension for
    Winthrop KL; Flume PA; Thomson R; Mange KC; Yuen DW; Ciesielska M; Morimoto K; Ruoss SJ; Codecasa LR; Yim JJ; Marras TK; van Ingen J; Wallace RJ; Brown-Elliott BA; Coulter C; Griffith DE
    Ann Am Thorac Soc; 2021 Jul; 18(7):1147-1157. PubMed ID: 33326356
    [No Abstract]   [Full Text] [Related]  

  • 8. Amikacin Liposome Inhalation Suspension in Refractory Mycobacterium avium Complex Lung Disease: A Profile of Its Use.
    Hoy SM
    Clin Drug Investig; 2021 Apr; 41(4):405-412. PubMed ID: 33723805
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amikacin liposome inhalation suspension for Mycobacterium avium complex pulmonary disease: A subgroup analysis of Japanese patients in the randomized, phase 3, CONVERT study.
    Morimoto K; Nonaka M; Yamazaki Y; Nakagawa T; Takasaki J; Tsuyuguchi K; Kitada S; Jumadilova Z; Yuen DW; Ciesielska M; Hasegawa N
    Respir Investig; 2024 Mar; 62(2):284-290. PubMed ID: 38277865
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A case of drug-induced organizing pneumonia caused by amikacin liposome inhalation suspension.
    Takao D; Takeda K; Takazono T; Ozasa M; Ito Y; Ashizawa N; Hirayama T; Iwanaga N; Takemoto S; Ide S; Tashiro M; Hosogaya N; Kido T; Sakamoto N; Obase Y; Okano S; Izumikawa K; Yanagihara K; Mukae H
    J Infect Chemother; 2023 Aug; 29(8):806-808. PubMed ID: 37098378
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aerosolized amikacin for treatment of pulmonary Mycobacterium avium infections: an observational case series.
    Davis KK; Kao PN; Jacobs SS; Ruoss SJ
    BMC Pulm Med; 2007 Feb; 7():2. PubMed ID: 17319962
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhaled amikacin for treatment of refractory pulmonary nontuberculous mycobacterial disease.
    Olivier KN; Shaw PA; Glaser TS; Bhattacharyya D; Fleshner M; Brewer CC; Zalewski CK; Folio LR; Siegelman JR; Shallom S; Park IK; Sampaio EP; Zelazny AM; Holland SM; Prevots DR
    Ann Am Thorac Soc; 2014 Jan; 11(1):30-5. PubMed ID: 24460437
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized Trial of Liposomal Amikacin for Inhalation in Nontuberculous Mycobacterial Lung Disease.
    Olivier KN; Griffith DE; Eagle G; McGinnis JP; Micioni L; Liu K; Daley CL; Winthrop KL; Ruoss S; Addrizzo-Harris DJ; Flume PA; Dorgan D; Salathe M; Brown-Elliott BA; Gupta R; Wallace RJ
    Am J Respir Crit Care Med; 2017 Mar; 195(6):814-823. PubMed ID: 27748623
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amikacin Liposome Inhalation Suspension for
    Golia A; Mahmood BR; Fundora Y; Thornby KA; Chahine EB
    Sr Care Pharm; 2020 Apr; 35(4):162-170. PubMed ID: 32192565
    [No Abstract]   [Full Text] [Related]  

  • 15. Mycobacterium avium Complex: Addressing Gaps in Diagnosis and Management.
    Daley CL; Winthrop KL
    J Infect Dis; 2020 Aug; 222(Suppl 4):S199-S211. PubMed ID: 32814943
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Laryngeal Injury Due to Amikacin Inhalation for Refractory Mycobacterium avium Complex Infection.
    Axiotakis LG; Enver N; Keating CL; Pitman MJ
    Chest; 2021 Apr; 159(4):e185-e187. PubMed ID: 34022015
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of Mycobacterium avium Complex Pulmonary Disease: When Should I Treat and What Therapy Should I Start?
    Nguyen MH; Daley CL
    Clin Chest Med; 2023 Dec; 44(4):771-783. PubMed ID: 37890915
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amikacin liposome inhalation suspension as a treatment for patients with refractory mycobacterium avium complex lung infection.
    Zhang Y; Hill AT
    Expert Rev Respir Med; 2021 Jun; 15(6):737-744. PubMed ID: 34039231
    [No Abstract]   [Full Text] [Related]  

  • 19. Safety of IV amikacin in the treatment of pulmonary non-tuberculous mycobacterial disease.
    Ellender CM; Law DB; Thomson RM; Eather GW
    Respirology; 2016 Feb; 21(2):357-62. PubMed ID: 26581837
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Open-Label Trial of Amikacin Liposome Inhalation Suspension in Mycobacterium abscessus Lung Disease.
    Siegel SAR; Griffith DE; Philley JV; Brown-Elliott BA; Brunton AE; Sullivan PE; Fuss C; Strnad L; Wallace RJ; Winthrop KL
    Chest; 2023 Oct; 164(4):846-859. PubMed ID: 37419144
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.